Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Peg-Intron · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | - |
| 2 | ACTIVE_COMPARATOR | - |
| 3 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Peg-Intron | DRUG | SC injection, weight based dosing, weekly, 48 weeks |
| REBETOL | DRUG | Capsules, weight based dosing, Q12 hrs daily, 48weeks |
| HCV 796 | DRUG | Capsules, 500 mg, Q 12 hrs. daily, 48 weeks |
Inclusion Criteria: * Infection with HCV genotype 1. * HCV- infected subjects naive to treatment. * HCV-infected non-responder subjects. Exclusion Criteria: * Women who are pregnant or breastfeeding. * ALT \>/ or = 5X the upper limit of normal. * AST \>/ or = 5X the upper limit of normal.
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | - | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | - | Undisclosed |
Peg-Intron is an investigational small molecule being studied for the treatment of Hepatitis C. It is currently in Phase 2 clinical development. The drug is being evaluated in patients with Hepatitis C, as part of a clinical trial program assessing its safety and clinical activity.
Peg-Intron is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE on the New York Stock Exchange. The company is conducting clinical research on this drug for the treatment of Hepatitis C.
Peg-Intron is currently in Phase 2 clinical development for Hepatitis C. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in a clinical trial to evaluate its safety and clinical activity in patients with Hepatitis C.
Peg-Intron has one completed clinical trial, identified as NCT00367887, titled 'A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects.' This Phase 2 study enrolled 246 participants with Hepatitis C in the United States and Puerto Rico.
Yes, Peg-Intron is also known as HCV-796. The clinical trial NCT00367887, which evaluates the safety and clinical activity of HCV-796, is the study for Peg-Intron. This alternative name is used in the trial title and documentation.